85
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

      review-article
      , MD 1 , , , MD 2 , , MD 3 , , MRCP (UK), PhD 4 , , MD 5 , , MD 6 , , MD 7 , 8 , , MD, PhD 9 , 10 , and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee
      Movement Disorders
      John Wiley & Sons, Inc.
      evidence‐based medicine, non‐motor symptoms, Parkinson's disease, randomized controlled trial

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Objective

          To update evidence‐based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD).

          Background

          The International Parkinson and Movement Disorder Society Evidence‐Based Medicine Committee's recommendations for treatments of PD were first published in 2002, updated in 2011, and now updated again through December 31, 2016.

          Methods

          Level I studies testing pharmacological, surgical, or nonpharmacological interventions for the treatment of nonmotor symptoms in PD were reviewed. Criteria for inclusion and quality scoring were as previously reported. The disorders covered were a range of neuropsychiatric symptoms, autonomic dysfunction, disorders of sleep and wakefulness, pain, fatigue, impaired olfaction, and ophthalmologic dysfunction. Clinical efficacy, implications for clinical practice, and safety conclusions are reported.

          Results

          A total of 37 new studies qualified for review. There were no randomized controlled trials that met inclusion criteria for the treatment of anxiety disorders, rapid eye movement sleep behavior disorder, excessive sweating, impaired olfaction, or ophthalmologic dysfunction. We identified clinically useful or possibly useful interventions for the treatment of depression, apathy, impulse control and related disorders, dementia, psychosis, insomnia, daytime sleepiness, drooling, orthostatic hypotension, gastrointestinal dysfunction, urinary dysfunction, erectile dysfunction, fatigue, and pain. There were no clinically useful interventions identified to treat non‐dementia‐level cognitive impairment.

          Conclusions

          The evidence base for treating a range of nonmotor symptoms in PD has grown substantially in recent years. However, treatment options overall remain limited given the high prevalence and adverse impact of these disorders, so the development and testing of new treatments for nonmotor symptoms in PD remains a top priority. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

          Related collections

          Most cited references142

          • Record: found
          • Abstract: found
          • Article: not found

          International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.

          The objective of this review was to update evidence-based medicine recommendations for treating motor symptoms of Parkinson's disease (PD).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neuropathic pain: principles of diagnosis and treatment.

            Neuropathic pain is caused by disease or injury of the nervous system and includes various chronic conditions that, together, affect up to 8% of the population. A substantial body of neuropathic pain research points to several important contributory mechanisms including aberrant ectopic activity in nociceptive nerves, peripheral and central sensitization, impaired inhibitory modulation, and pathological activation of microglia. Clinical evaluation of neuropathic pain requires a thorough history and physical examination to identify characteristic signs and symptoms. In many cases, other laboratory investigations and clinical neurophysiological testing may help identify the underlying etiology and guide treatment selection. Available treatments essentially provide only symptomatic relief and may include nonpharmacological, pharmacological, and interventional therapies. Most extensive evidence is available for pharmacological treatment, and currently recommended first-line treatments include antidepressants (tricyclic agents and serotonin-norepinephrine reuptake inhibitors) and anticonvulsants (gabapentin and pregabalin). Individualized multidisciplinary patient care is facilitated by careful consideration of pain-related disability (eg, depression and occupational dysfunction) as well as patient education; repeat follow-up and strategic referral to appropriate medical/surgical subspecialties; and physical and psychological therapies. In the near future, continued preclinical and clinical research and development are expected to lead to further advancements in the diagnosis and treatment of neuropathic pain.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT.

              Our objective was to evaluate the efficacy of probiotics and prebiotics in patients with Parkinson disease (PD) and constipation.
                Bookmark

                Author and article information

                Contributors
                klaus.seppi@tirol-kliniken.at
                Journal
                Mov Disord
                Mov. Disord
                10.1002/(ISSN)1531-8257
                MDS
                Movement Disorders
                John Wiley & Sons, Inc. (Hoboken, USA )
                0885-3185
                1531-8257
                17 January 2019
                February 2019
                : 34
                : 2 ( doiID: 10.1002/mds.v34.2 )
                : 180-198
                Affiliations
                [ 1 ] Department of Neurology Medical University Innsbruck Innsbruck Austria
                [ 2 ] Institute of Psychiatry Psychology & Neuroscience at King's College and Parkinson Foundation International Centre of Excellence at King's College Hospital Denmark Hill London United Kingdom
                [ 3 ] Serviço de Neurologia Hospital Santa Maria Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Lisboa Portugal
                [ 4 ] Edmond J Safra Program in Parkinson Disease, Movement Disorder Clinic Toronto Western Hospital, and the University of Toronto Department of Medicine Toronto Ontario Canada
                [ 5 ] Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders Danube Hospital Vienna Austria
                [ 6 ] Institute of Cardiology Research University of Buenos Aires, National Research Council Buenos Aires Argentina
                [ 7 ] Departments of Psychiatry and Neurology Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA
                [ 8 ] Parkinson's Disease and Mental Illness Research Education and Clinical Centers, Philadelphia Veterans Affairs Medical Center Philadelphia Pennsylvania USA
                [ 9 ] CHDI Management/CHDI Foundation Princeton NJ USA
                [ 10 ] Instituto de Medicina Molecular University of Lisbon Lisbon Portugal
                Author notes
                [*] [* ] Corresponding author: Dr. Klaus Seppi, Department of Neurology, Medical University Innsbruck, Anichstrasse 35, AT‐6020 Innsbruck, Austria; E‐mail: klaus.seppi@ 123456tirol-kliniken.at
                Author information
                https://orcid.org/0000-0003-2815-0505
                https://orcid.org/0000-0001-9069-6512
                Article
                MDS27602
                10.1002/mds.27602
                6916382
                30653247
                f61ce591-aff5-4e74-8e10-1ebbad085907
                © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 15 August 2018
                : 26 November 2018
                : 12 December 2018
                Page count
                Figures: 0, Tables: 10, Pages: 19, Words: 17501
                Funding
                Funded by: International Parkinson and Movement Disorder Society , open-funder-registry 10.13039/100008440;
                Categories
                MDS Commissioned Review
                MDS Commissioned Review
                Custom metadata
                2.0
                February 2019
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.7.3 mode:remove_FC converted:17.12.2019

                Medicine
                evidence‐based medicine,non‐motor symptoms,parkinson's disease,randomized controlled trial

                Comments

                Comment on this article